Jacobs Levy Equity Management, Inc Fate Therapeutics Inc Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,587,900 shares of FATE stock, worth $2.56 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,587,900
Previous 1,694,217
6.28%
Holding current value
$2.56 Million
Previous $5.56 Million
-0.0%
% of portfolio
0.02%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding FATE
# of Institutions
175Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$21.2 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$16.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$16.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$8.97 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$8.46 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $156M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...